📊 IMNN Key Takeaways
Is IMNN a Good Investment? Thesis Analysis
Imunon faces critical cash runway depletion with $14.2M annual free cash flow burn against only $8.8M cash reserves, providing less than 12 months of operations without external funding. The company generates merely $500K in annual revenue against $14.5M in net losses, indicating a pre-commercial product stage with no demonstrated path to profitability. Unsustainable capital structure cannot support $6.1M long-term debt from operations, creating acute refinancing and dilution risk.
Why Buy IMNN? Key Strengths
- Improving loss trajectory YoY (22.2% net income improvement, 59.7% EPS improvement) demonstrates cost discipline
- Solid near-term liquidity with 2.32x current ratio and 2.32x quick ratio providing near-term solvency cushion
- Moderate leverage at 0.86x debt-to-equity with minimal capex ($280.6K) appropriate for development stage
IMNN Investment Risks to Consider
- Critical cash runway - $8.8M cash against $14.2M annual FCF burn creates sub-12-month survival horizon without capital raise
- Revenue generation failure - $500K revenue against $14.5M net loss indicates pre-commercial development stage with unproven market traction
- Debt servicing crisis - negative $74.3x interest coverage ratio means operating income cannot service $6.1M long-term debt obligations
- Imminent equity dilution risk - company will require near-term capital raises to fund operations, destroying existing shareholder value
Key Metrics to Watch
- Monthly cash burn rate and ending cash balance - critical indicator of runway to funding need
- Revenue growth and product commercialization milestones - only measure of fundamental viability
- Debt refinancing announcements and terms - indicates market access to capital and covenant compliance
IMNN Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.32x current ratio provides a solid financial cushion.
IMNN Profitability Ratios
IMNN vs Healthcare Sector
How Imunon, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IMNN Overvalued or Undervalued?
Based on fundamental analysis, Imunon, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IMNN Balance Sheet & Liquidity
IMNN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Imunon, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-16.94 indicates the company is currently unprofitable.
IMNN Growth Metrics (YoY)
IMNN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $125.0K | -$3.5M | $-0.37 |
| Q2 2023 | $125.0K | -$5.5M | $-0.61 |
| Q1 2023 | $125.0K | -$5.5M | $-0.68 |
| Q3 2022 | $125.0K | -$5.4M | $-0.87 |
| Q2 2022 | $125.0K | -$5.4M | $-0.87 |
| Q1 2022 | $125.0K | -$5.7M | $-1.82 |
| Q3 2021 | $125.0K | -$5.4M | N/A |
| Q2 2021 | $125.0K | -$5.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IMNN Capital Allocation
IMNN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Imunon, Inc. (CIK: 0000749647)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMNN
What is the AI rating for IMNN?
Imunon, Inc. (IMNN) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMNN's key strengths?
Claude: Improving loss trajectory YoY (22.2% net income improvement, 59.7% EPS improvement) demonstrates cost discipline. Solid near-term liquidity with 2.32x current ratio and 2.32x quick ratio providing near-term solvency cushion.
What are the risks of investing in IMNN?
Claude: Critical cash runway - $8.8M cash against $14.2M annual FCF burn creates sub-12-month survival horizon without capital raise. Revenue generation failure - $500K revenue against $14.5M net loss indicates pre-commercial development stage with unproven market traction.
What is IMNN's revenue and growth?
Imunon, Inc. reported revenue of $500.0K.
Does IMNN pay dividends?
Imunon, Inc. does not currently pay dividends.
Where can I find IMNN SEC filings?
Official SEC filings for Imunon, Inc. (CIK: 0000749647) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMNN's EPS?
Imunon, Inc. has a diluted EPS of $-6.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMNN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Imunon, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMNN stock overvalued or undervalued?
Valuation metrics for IMNN: ROE of -205.3% (sector avg: 15%), net margin of -2,899.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMNN stock in 2026?
Our dual AI analysis gives Imunon, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMNN's free cash flow?
Imunon, Inc.'s operating cash flow is $-13.9M, with capital expenditures of $280.6K. FCF margin is -2,835.4%.
How does IMNN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,899.0% (avg: 12%), ROE -205.3% (avg: 15%), current ratio 2.32 (avg: 2).